Form 8-K - Current report:
SEC Accession No. 0001104659-26-078337
Filing Date
2026-06-26
Accepted
2026-06-26 17:30:25
Documents
11
Period of Report
2026-06-26
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2619105d1_8k.htm   iXBRL 8-K 22434
  Complete submission text file 0001104659-26-078337.txt   187335

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA otlk-20260626.xsd EX-101.SCH 3047
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20260626_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20260626_pre.xml EX-101.PRE 22380
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2619105d1_8k_htm.xml XML 3193
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 261130693
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)